Literature DB >> 10844118

Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice.

W P Spooren1, F Gasparini, H van der Putten, M Koller, S Nakanishi, R Kuhn.   

Abstract

In metabotropic glutamate receptor 2 (mGlu(2)) knockout mice, the group 2 metabotropic glutamate receptor agonist LY314582 (20 mg/kg, i.p.), a racemate of LY354740, inhibits neither spontaneous nor phencyclidine (PCP)-induced (2.5 mg/kg, s.c.) locomotor activity. Since LY314582 attenuated spontaneous and PCP-induced locomotor activity in wild-type control mice, these data indicate that the effects of LY314582 are mediated via the mGlu(2) receptor and not via the mGlu(3) receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844118     DOI: 10.1016/s0014-2999(00)00269-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells.

Authors:  Lia Baki; Miguel Fribourg; Jason Younkin; Jose Miguel Eltit; Jose L Moreno; Gyu Park; Zhanna Vysotskaya; Adishesh Narahari; Stuart C Sealfon; Javier Gonzalez-Maeso; Diomedes E Logothetis
Journal:  Pflugers Arch       Date:  2016-01-16       Impact factor: 3.657

Review 2.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

3.  mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Authors:  Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank
Journal:  Psychopharmacology (Berl)       Date:  2016-02-10       Impact factor: 4.530

4.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Authors:  Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

5.  Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.

Authors:  A-M Linden; H Shannon; M Baez; J L Yu; A Koester; D D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

6.  Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Authors:  Michael P Johnson; David Barda; Thomas C Britton; Renee Emkey; William J Hornback; G Erik Jagdmann; David L McKinzie; Eric S Nisenbaum; Joseph P Tizzano; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

7.  Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Authors:  Andrea M Bradford; Kevin M Savage; Declan N C Jones; Mikhail Kalinichev
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

Review 8.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 10.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.